A Need For An Antiviral Strategy on Flavivirus Infections

A collaboration from Harvard Medical School, Dana-Farber Cancer Institute, Moderna Therapeutics and more looked into how small molecules can block the viral replication cycle at an early stage of flaviviruses, which also includes the dengue virus. There has been an unmet medical need to prevent flavivirus infections since there are no approved drugs to prevent these infections without causing non-immune children to more severe diseases once they have contracted the virus. One of the methods called biotinylation was performed with purified ZIKV sE and biotin-PEG2-NHS to test if this method may help with target-based screening and medicinal chemistry optimization in inhibiting flavivirus E proteins. Perhaps this research would be a stepping stone in finding a vaccine for the virus.

Read more about the study here